Erik Harris compensation by year
Ultragenyx Pharmaceutical Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $619,692 |
| Bonus | $0 |
| Stock awards | $2,407,560 |
| Option awards | $712,257 |
| Non-equity incentive | $291,563 |
| Pension and deferred compensation | $0 |
| All other | $14,000 |
| Total | $4,045,072 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Ultragenyx Pharmaceutical Inc. DEF 14A filed March 27, 2026, accession 0001308179-26-000174, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 33,627 | $773,421 | — |
| RSU | 20,693 | $475,939 | — |
| RSU | 16,813 | $386,699 | — |
| RSU | 16,500 | $379,500 | — |
| PSU | 12,920 | $297,160 | — |
| RSU | 3,500 | $80,500 | — |
| Option | 30,246 | — | $42.92 |
| Option | 1,556 | — | $67.37 |
| Option | 19,237 | — | $53.69 |
| Option | 12,312 | — | $45.65 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Ultragenyx Pharmaceutical Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2025 proxy (filed March 27, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-04-16 | Grant or award derivative | — | 49,960 | $0.00 | 49,960 |
| 2026-04-16 | Grant or award | — | 28,895 | $0.00 | 118,410 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Ultragenyx Pharmaceutical discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $933,000 | $2,393,219 | $14,067 | $3,806,786 |
| Involuntary termination without cause | $622,000 | $0 | $9,378 | $942,378 |
Per the Potential Payments Upon Termination or Change in Control table in Ultragenyx Pharmaceutical Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Ultragenyx Pharmaceutical’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Emil Kakkis | President and Chief Executive Officer | $11,405,535 |
| Erik Harris · this page | Chief Commercial Officer and Executive Vice President | $4,045,072 |
| Eric Crombez | Chief Medical Officer and Executive Vice President | $4,002,173 |
| Howard Horn | Chief Financial Officer, Corporate Strategy and Executive Vice President | $3,750,607 |
| Karah Parschauer | Chief Legal Officer & Corporate Affairs, Executive Vice President | $3,509,313 |
The full Ultragenyx Pharmaceutical compensation record
free company briefThis page is one person within Ultragenyx Pharmaceutical's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Ultragenyx Pharmaceutical's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Ultragenyx Pharmaceutical's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat